Pharma Stock Roundup: FDA Nod to LLY’s Kisunla, SNY’s Dupixent Gets EU Nod for COPD

Eli Lilly (LLY) wins FDA approval for its Alzheimer’s disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron’s Dupixent gets approval for COPD in Europe.